

## Daftar Pustaka

1. Smeland S, Bielack SS, Whelan J, Bernstein M, Hogendoorn P, Krailo MD, et al. Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American osteosarcoma study) cohort. *Eur J Cancer*. 2019;109:36–50.
2. Song K, Song J, Chen F, Lin K, Ma X, Jiang J. Prognostic nomograms for predicting overall and cancer-specific survival of high-grade osteosarcoma patients. *J Bone Oncol*. 2018;13:106–13.
3. Gorlick R, Janeway K, Lessnick S, Randall RL, Marina N. Children's oncology Group's 2013 blueprint for research: bone tumors. *Pediatr Blood Cancer*. 2013; 60:1009–15.
4. Ikuta K, Kawamoto T, Hara H, Fukase N, Morishita M, Kuroda R, et al. Solitary pancreatic lesion as the initial metastasis from osteosarcoma: report of a rare case. *J Orthop Sci*. 2020;25:724–8.
5. Fujiwara T, Oda M, Yoshida A, et al. Atypical manifestation of lung metastasis 17 years after initial diagnosis of low-grade central osteosarcoma. *J Orthop Sci*. 2017;22:357–61.
6. Kaste SC, Pratt CB, Cain AM, Jones-Wallace DJ, Rao BN. Metastases detected at the time of diagnosis of primary pediatric extremity osteosarcoma at diagnosis: imaging features. *Cancer*. 1999;86:1602–

8. Picci, P. (2007). Osteosarcoma (osteogenic sarcoma). *Orphanet journal of rare diseases*, 2, 1-4.
7. Estrada-Villaseor E, Escamilla-Urbe R, De la Garza-Montano P, Dominguez- Rubio R, Martinez-Lopez V, Avila-Luna A, et al. Association of metastasis with clinicopathological data in Mexican patients with osteosarcoma, Giant cell tumor of bone and chondrosarcoma. *Asian Pac J Cancer Prev*. 2015;16:7689–94.
8. Salah S, Toubasi S. Factors predicting survival following complete surgical remission of pulmonary metastasis in osteosarcoma. *Mol Clin Oncol*. 2015;3:157–62.
9. Zhang C, Guo X, Xu Y, Han X, Cai J, Wang X, et al. Lung metastases at the initial diagnosis of high-grade osteosarcoma: prevalence, risk factors and prognostic factors. A large population-based cohort study. *Sao Paulo Med J*. 2019;137:423–9.
10. Kusma J, Young C, Yin H, Stanek JR, Yeager N, Aldrink JH. Pulmonary nodule size <5 mm still warrants investigation in patients with osteosarcoma and Ewing sarcoma. *J Pediatr Hematol Oncol*. 2017;39:184–7
11. Federman N, Bernthal N, Eilber FC, et al. The multidisciplinary management of osteosarcoma. *Curr Treat Options Oncol* 2009; 10: 82-93.
12. Fuchs N, Bielack SS, Epler D, et al. Long-term results of the co-operative German-Austrian-Swiss osteosarcoma study group's protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs. *Amt Oncol* 1998;9:893-899.

13. Milla'n JL (2006) Mammalian alkaline phosphatases. Wiley- VCH, Weinheim
14. Weiss MJ, Ray K, Henthorn PS et al (1988) Structure of the human liver/bone/kidney alkaline phosphatase gene. J Biol Chem 263:12002–12010
15. Singal AK, Agarwala S. Tumour Markers in Pediatric Solid Tumours. J Indian Assoc Pediatr Surg. 2005. Jul-Sept, 10 (3); P. 183 – 190
16. Limmahakhun S, Pothacharoen P, Theera-Umpon N, et al. Relationships between Serum Biomarker Levels and Clinical Presentation of Human Osteosarcomas. J Cancer Asian Pacific. 2011, vol 12; P. 1-6
17. Shim, H., Dolde, C., Lewis, B. C., Wu, C. S., Dang, G., et al. (1997) c-Myc transactivation of LDH-A: implications for tumor metabolism and growth. Proc. Natl. Acad. Sci. USA 94, 6658 – 6663.
18. Cheung KL, Robertson FR. Objective measurement of remission and progression in metastatic breast cancer by the use of serum tumour markers. Minerva Chir 2003;58(3):297-303
19. Ren HY, Sun LL, Li HY, et al. Prognostic Significance of Serum Alkaline Phosphatase Level in Osteosarcoma: A Meta-Analysis of Published Data. BioMed Research International. 2015. Oct, 2015;1-11
20. Chen J, Sun MX, Hua YQ, et al. Prognostic significance of serum lactate dehydrogenase level in osteosarcoma: a meta- analysis. J Cancer Res Clin Oncol. 2014, Mar, 140:1205–1210
21. Augoff, K. and Grabowski, K. (2004) [Significance of lactate dehydrogenase measurements in diagnosis of malignancies]. Pol. Merkur. Lekarski. 17, 644–

647.

22. Scully SP, Temple HT, O’Keefe RJ, Mankin HJ, Gebhardt M. The surgical treatment of patients with osteosarcoma who sustain a pathologic fracture. *Clin Orthop Relat Res.* 1996;227–32.
23. O’Hara JM, Hutter RV, Foote FW Jr, Miller T, Woodard HQ. An analysis of thirty patients surviving longer than ten years after treatment for osteogenic sarcoma. *J Bone Joint Surg Am.* 1968; 50:335–54.
24. Xie L, Guo W, Li Y, Ji T, Sun X. Pathologic fracture does not influence local recurrence and survival in high-grade extremity osteosarcoma with adequate surgical margins. *J Surg Oncol.* 2012; 106:820–5.
25. Lee RK, Chu WC, Leung JH, Cheng FW, Li CK. Pathological fracture as the presenting feature in pediatric osteosarcoma. *Pediatr Blood Cancer.* 2013; 60:1118–21.
26. Yang M. Prognostic role of pathologic fracture in osteosarcoma: Evidence based on 1,677 subjects. *J Cancer Res Ther.* 2015; 11:264–7.
27. Matthew T , Martin L. Management of Osteosarcoma Pulmonary Metastases. *Seminars in Pediatric Surgery* . 2006. 15 ; p 25-29
28. Duffaud F, Digue L, Mercier C, Dales JP, Baciuchka-Palmaro M, Volot F, et al. Recurrences following primary osteosarcoma in adolescents and adults previously treated with chemotherapy. *Eur J Cancer (Oxford Engl 1990)* (2003) 39(14):2050–7.
29. Strauss SJ, McTiernan A, Whelan JS. Late relapse of osteosarcoma: implications for follow-up and screening. *Pediatr Blood Cancer* (2004)

43(6):692–7.

30. Ferrari S, Briccoli A, Mercuri M, Bertoni F, Cesari M, Longhi A, et al. Late relapse in osteosarcoma. *J Pediatr Hematol/Oncol* (2006) 28(7):418–22.
31. Salah, Samer, and Samar Toubasi. "Factors predicting survival following complete surgical remission of pulmonary metastasis in osteosarcoma." *Molecular and clinical oncology* 3.1 (2015): 157-162.
32. Song K, Song J, Lin K, Chen F, Ma X, Jiang J, et al. Survival analysis of patients with metastatic osteosarcoma: a surveillance, epidemiology, and end results population-based study. *Int Orthop* (2019) 43(8):1983–91.
33. Kim SH, Shin KH, Moon SH, et al. Reassessment of alkaline phosphatase as serum tumor marker with high specificity in osteosarcoma. *Cancer Medicine*. 2017;6(6):1311–1322.
34. Hao H, Chen L, Huang D, et al. Meta-analysis of alkaline phosphatase and prognosis for osteosarcoma. *European Journal of Cancer Care* 2017;26, e12536(5).
35. Ren, H. Y., L. L. Sun, H. Y. Li, and Z. M. Ye. 2015. Prognostic significance of serum alkaline phosphatase level in osteosarcoma: a meta-analysis of published data. *BioMed Res. Int.* 2015:160835.
36. Vasquez, Liliana, et al. "Analysis of prognostic factors in high-grade osteosarcoma of the extremities in children: a 15-year single-institution experience." *Frontiers in oncology* 6 (2016): 22.
37. Bacci G, Longhi A, Versari M, Mercuri M, Briccoli A, Picci P. Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant

- chemotherapy: 15-year experience in 789 patients treated at a single institution. *Cancer* (2006) **106**:1154–61. doi:10.1002/cncr.21724
38. Bacci G, Longhi A, Ferrari S, Briccoli A, Donati D, De Paolis M, et al. Prognostic significance of serum lactate dehydrogenase in osteosarcoma of the extremity: experience at Rizzoli on 1421 patients treated over the last 30 years. *Tumori* (2004) **90**:478–84.
  39. Zuo D, Zheng L, Sun W, Hua Y, Cai Z. Pathologic fracture does not influence prognosis in stage IIB osteosarcoma: a case-control study. *World J Surg Oncol* 2013;11:148.
  40. Bacci G, Ferrari S, Longhi A, et al. Nonmetastatic osteosarcoma of the extremity with pathologic fracture at presentation: local and systemic control by amputation or limb salvage after preoperative chemotherapy. *Acta Orthop Scand* 2003;74:449–454.
  41. Bramer JA, Abudu AA, Grimer RJ, Carter SR, Tillman RM. Do pathological fractures influence survival and local recurrence rate in bony sarcomas? *Eur J Cancer* 2007;43:1944–1951.
  42. Ferguson PC, McLaughlin CE, Griffin AM, et al. Clinical and functional outcomes of patients with a pathologic fracture in high-grade osteosarcoma. *J Surg Oncol* 2010;102:120–124.
  43. Chandrasekar CR, Grimer RJ, Carter SR, et al. Pathological fracture of the proximal femur in osteosarcoma: need for early radical surgery? *ISRN Oncol* 2012;2012:512389.
  44. Zhou Y, Lu Q, Xu J, Yan R, Zhu J, Xu J, Jiang X, Li J, Wu F. The effect of

- pathological fractures on the prognosis of patients with osteosarcoma: a meta-analysis of 14 studies. *Oncotarget*. 2017 Aug 21;8(42):73037-73049.
45. Bieling P, Rehan N, Winkler P, Helmke K, Maas R, Fuchs N, et al. Tumor size and prognosis in aggressively treated osteosarcoma. *J Clin Oncol* 1996;14:848–58.
46. Shin KH, Moon SH, Suh JS, Yang WI. Tumor volume change as a predictor of chemotherapeutic response in osteosarcoma. *Clin Orthop Relat Res* 2000;376:200–8.
47. Holscher HC, Bloem JL, Nooy MA, Taminiau AH, Eulderink F, Hermans J. The value of MR imaging in monitoring the effect of chemotherapy on bone sarcomas. *AJR Am J Roentgenol* 1990;154:763–9.
48. Hudson M, Jaffe MR, Jaffe N, Ayala A, Raymond AK, Carrasco H, et al. Pediatric osteosarcoma: therapeutic strategies, results, and prognostic factors derived from a 10-year experience. *J Clin Oncol* 1990;8:1988–97.
49. Munajat I, Zulmi W, Norazman MZ, Wan Faisham WI. Tumour volume and lung metastasis in patients with osteosarcoma. *J Orthop Surg (Hong Kong)*. 2008 Aug;16(2):182-5.